Dr. Kevin Tracey

It works.

We've seen very impressive open-label trials in some diabetes models and type 2 diabetes studies.

And we've seen very impressive preclinical results in, again, diabetes, in multiple sclerosis.

We've seen pilot clinical trials in lupus arthritis.

We've seen pilot clinical trials in other inflammatory conditions.

So I am agreeing with you 100%.

This is the tip of the iceberg.

There's work to do.

There's clinical trials to be done.

There's going to be money to be raised and spent.

But I think you're going to see it happen because patients are going to demand this.

I mean, we talked about the expense of biologics.

We talked about their invasiveness.

We talked about their immunosuppressive black box warnings.

We left out the fact they only work half the time.

Yeah, 40%, 50% if you're lucky, right?

So the demand is there.

And I wrote this book for the simple reason of establishing a platform of basic information for patients, for doctors, and for family and friends interested in the vagus nerve, that this is what we know to be true in the lab and in the clinic.

This is what we know to be false.

And these are the important things that I'm urging my colleagues to double down and work harder on because we've got a lot more to do.